Keyphrases
Multiple Sclerosis Treatment
63%
C-C Chemokine Receptor Type 5 (CCR5)
57%
IFNAR1
55%
Disease-modifying Therapy
55%
Multiple Sclerosis
55%
Immune-related Genes
50%
Glatiramer Acetate
44%
Pharmacogenetics
44%
Allelic Combination
44%
Composite Marker
44%
Treatment Efficacy
22%
Treatment Response
17%
Transforming Growth factor-β1 (TGF-β1)
17%
Genetic Variants
17%
Composite Biomarkers
12%
Non-responders
12%
Pharmacogenetic Study
12%
Epigenetic Biomarkers
12%
Joint Contribution
11%
APSampler
11%
IFN Response
11%
Clinical Prognosis
11%
Additive Effect
11%
Polymorphic Loci
11%
Allelic Variants
11%
Optimal Response
11%
Epistatic Interactions
11%
Cumulative Effects
11%
Rs1130864
8%
Republic of Bashkortostan
8%
Moscow Region
8%
Logical Variable
8%
Polymorphic Variants
6%
CCR5 Gene
6%
Treatment Choice
6%
Should Be Given
6%
CTLA-4 Gene
6%
Autoimmune
6%
Bioinformatics Algorithms
6%
Neurodegenerative Diseases
6%
Therapy Choice
6%
Therapy Response
6%
DRB1 Gene
6%
Clinical Criteria
6%
Mode of Action
6%
Pharmacological Analysis
6%
Long-term Medication
6%
Biochemistry, Genetics and Molecular Biology
Allele
100%
Genetic Divergence
77%
IFNAR1
62%
CCR5
44%
Genetics
44%
PTGS1
44%
Immune Response Gene
44%
Genetic Background
22%
Genetic Determinism
22%
Smoking
22%
Polymorphic Locus
11%
Immunology and Microbiology
Multiple Sclerosis
88%
CCR5
66%
Allele
55%
Immune Response Gene
51%
Glatiramer Acetate
44%
Pharmacogenetics
44%
Genetic Variability
40%
Heredity
22%
Pharmacogenetic Testing
22%
Polymorphic Locus
11%
